SEARCH

SEARCH BY CITATION

References

  • 1
    Burch J, Corbett M, Stock C et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis2009; 9: 537545.
  • 2
    Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev2010; 2: CD001265.
  • 3
    Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ2009; 339: b3172.
  • 4
    The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet1998; 352: 18771881.
  • 5
    Hayden FG, Osterhaus AD, Treanor JJ et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med1997; 337: 874880.
  • 6
    Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet2000; 355: 18451850.
  • 7
    Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA2000; 283: 10161024.
  • 8
    WHO. Guidelines for Pharmalogial Management of Pandemic Influenza A(H1N1)2009 and other Influenza Viruses. 2010.
  • 9
    Kawai N, Ikematsu H, Iwaki N et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis2005; 40: 13091316.
  • 10
    Kawai N, Ikematsu H, Hirotsu N et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007–2008 and 2008–2009 influenza seasons. Clin Infect Dis2009; 49: 18281835.
  • 11
    Aoki FY, Macleod MD, Paggiaro P et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother2003; 51: 123129.
  • 12
    Matsuzaki Y, Mizuta K, Aoki Y et al. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J2010; 7: 53.
  • 13
    Sugaya N, Mitamura K, Yamazaki M et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis2007; 44: 197202.
  • 14
    Duval X, Van der Werf S, Blanchon T et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med2010; 7: e1000362.
  • 15
    Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med2002; 54: 14811496.
  • 16
    Stuart BC, Simoni-Wastila L, Zuckerman IH et al. Impact of maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with chronic obstructive pulmonary disease. Am J Geriatr Pharmacother2010; 8: 441453.
  • 17
    Bates JA, Whitehead R, Bolge SC, Kim E. Correlates of medication adherence among patients with bipolar disorder: results of the Bipolar Evaluation of Satisfaction and Tolerability (BEST) Study: a nationwide cross-sectional survey. Prim Care Companion J Clin Psychiatry2010; 12: pii: PCC.09m00883.
  • 18
    Kirchmayer U, Agabiti N, Belleudi V et al. Socio-demographic differences in adherence to evidence-based drug therapy after hospital discharge from acute myocardial infarction: a population-based cohort study in Rome, Italy. J Clin Pharm Ther2011; doi: 10.1111/j.1365-2710.2010.01242.x.
  • 19
    Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer’s disease patients receiving oral therapy. Curr Med Res Opin2010; 26: 1957.
  • 20
    Mulazzi I, Cambou JP, Girerd X, Nicodeme R, Chamontin B, Amar J. Six-item self-administered questionnaires in the waiting room: an aid to explain uncontrolled hypertension in high-risk patients seen in general practice. J Am Soc Hypertens2009; 3: 221227.
  • 21
    Mo R, Chen J, Grolleau-Julius A, Murphy HS, Richardson BC, Yung RL. Estrogen regulates CCR gene expression and function in T lymphocytes. J Immunol2005; 174: 60236029.
  • 22
    Roden AC, Moser MT, Tri SD et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol2004; 173: 60986108.
  • 23
    He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet1999; 37: 471484.
  • 24
    Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet2003; 42: 107121.
  • 25
    Lin JH, Chiba M, Chen IW, Nishime JA, Vastag KJ. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. Drug Metab Dispos1996; 24: 12981306.
  • 26
    Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. J Gen Intern Med2001; 16: 266275.
  • 27
    Suzuki E, Ichihara K. The course of fever following influenza virus infection in children treated with oseltamivir. J Med Virol2008; 80: 10651071.
  • 28
    Kawai N, Iwaki N, Kawashima T et al. [Effectiveness of oseltamivir on influenza and influencing factors: age of patients, type of influenza virus and timing of initial administration]. Kansenshogaku Zasshi2003; 77: 423429.
  • 29
    Heinonen S, Silvennoinen H, Lehtinen P et al. Early oseltamivir treatment of influenza in children 1–3 years of age: a randomized controlled trial. Clin Infect Dis2010; 51: 887894.
  • 30
    Lee N, Chan PK, Choi KW et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther2007; 12: 501508.